Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 423

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1

Open access
Rubin, Stephen C., Benjamin, Ivor, Behbakht, Kian, Takahashi, Hiroyuki, Morgan, Mark A., LiVolsi, Virginia A., Berchuck, Andrew, Muto, Michael G., Garber, Judy E., Weber, Barbara L., Lynch, Henry T., Boyd, Jeff·1996·New England Journal of Medicine
DOI 10.1056/nejm199611073351901
Open this paper in CoChat — free account

Abstract

BACKGROUND: We tested the hypothesis that ovarian cancers associated with germ-line mutations of BRCA1 have distinct clinical and pathological features as compared with sporadic ovarian cancers. METHODS: We reviewed clinical and pathological data on patients with primary epithelial ovarian cancer found to have germ-line mutations of BRCA1. Survival among patients with advanced-stage cancer and such mutations was compared with that in control patients matched stage, grade, and histologic subtype of the tumors. A combination of single-strand conformation and sequencing analyses was used to examine the 22 coding exons and intronic splice-donor and splice-acceptor regions of BRCA1 for mutations in pathological specimens. Alternatively, some patients were known to be obligate carriers of the mutant BRCA1 gene because of their parental relationships with documented mutant-gene carriers. RESULTS: We identified 53 patients with germ-line mutations of BRCA1. The average age at diagnosis was 48 years (range, 28 to 78). Histologic examination in 43 of the 53 patients showed serous adenocarcinoma. Thirty-seven tumors were of grade 3, 11 were of grade 2, 2 were of grade 1, and 3 were of low malignant potential. In 38 patients, the tumors were of stage III; 9 patients (including those with tumors of low malignant potential) had stage I disease, 5 had stage IV, and 1 had stage II. As of June 1996, with a median follow-up among survivors of 71 months from diagnosis, 20 patients had died of ovarian cancer, 27 had no evidence of the disease, 4 were alive with the disease, and 2 had died of other diseases. Actuarial median survival for the 43 patients with and advanced-stage disease was 77 months, as compared with 29 months for the matched controls (P<0.001). CONCLUSIONS: As compared with sporadic ovarian cancers, cancers associated with BRCA1 mutation appear to have a significantly more favorable clinical course.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199611073351901

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 423

Metadata

Authors
Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garber, J. E., Weber, B. L., Lynch, H. T., & Boyd, J.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
1996-11-07
Volume
335
Issue
19
Pages
1413-1416
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejm199611073351901
OpenAlex
W2329417450
Cited by
423
References
11
FWCI
17.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1. https://app.cochat.ai/papers/10.1056/nejm199611073351901
The paper
Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garber, J. E., Weber, B. L., Lynch, H. T., & Boyd, J. (1996). Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1. New England Journal of Medicine. https://doi.org/10.1056/nejm199611073351901

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.